Skip to main content

Compare Stocks

Date Range: 

 Gilead SciencesModernaBiogenBioNTechSeagen
SymbolNASDAQ:GILDNASDAQ:MRNANASDAQ:BIIBNASDAQ:BNTXNASDAQ:SGEN
Price Information
Current Price$68.53$161.38$280.21$192.77$147.50
52 Week RangeBuyHoldHoldHoldBuy
MarketRank™
Overall Score2.81.61.51.11.5
Analysis Score4.32.11.12.23.3
Community Score3.33.03.02.62.5
Dividend Score3.30.00.00.00.0
Ownership Score1.70.81.70.01.7
Earnings & Valuation Score1.31.91.90.60.0
Analyst Ratings
Consensus RecommendationBuyHoldHoldHoldBuy
Consensus Price Target$100.59$162.44$305.57$143.38$188.92
% Upside from Price Target46.78% upside0.66% upside9.05% upside-25.62% downside28.08% upside
Trade Information
Market Cap$85.95 billion$64.80 billion$42.19 billion$46.56 billion$26.77 billion
Beta0.511.730.53-1.741.11
Average Volume8,248,25911,760,8451,188,6972,590,4841,106,633
Sales & Book Value
Annual Revenue$22.45 billion$60.21 million$14.38 billion$121.63 million$916.71 million
Price / Sales3.831,076.212.93382.7829.20
Cashflow$8.13 per shareN/A$39.25 per shareN/AN/A
Price / Cash8.43N/A7.14N/AN/A
Book Value$17.90 per share$3.49 per share$73.93 per share$2.44 per share$10.95 per share
Price / Book3.8346.243.7979.0013.47
Profitability
Net Income$5.39 billion$-514,020,000.00$5.89 billion$-200,540,000.00$-158,650,000.00
EPS$6.14($1.55)$33.57($0.95)($1.33)
Trailing P/E Ratio70.65N/A9.28N/A58.07
Forward P/E Ratio9.7815.4411.1413.99N/A
P/E Growth0.670.531.04N/AN/A
Net Margins5.48%-242.73%35.63%-250.12%25.34%
Return on Equity (ROE)37.77%-28.11%51.00%-66.72%20.46%
Return on Assets (ROA)12.76%-20.31%23.54%-41.73%16.67%
Dividend
Annual Payout$2.84N/AN/AN/AN/A
Dividend Yield4.14%N/AN/AN/AN/A
Three-Year Dividend Growth30.77%N/AN/AN/AN/A
Payout Ratio46.25%N/AN/AN/AN/A
Years of Consecutive Dividend Growth1 YearsN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.65%0.04%0.69%N/AN/A
Current Ratio3.25%2.43%2.06%4.07%3.65%
Quick Ratio3.15%2.43%1.79%4.02%3.49%
Ownership Information
Institutional Ownership Percentage76.36%51.21%83.51%10.75%87.15%
Insider Ownership Percentage0.13%29.20%0.54%N/A31.10%
Miscellaneous
Employees13,6001,3009,1001,9412,092
Shares Outstanding1.25 billion401.53 million150.56 million241.52 million181.48 million
Next Earnings Date7/29/2021 (Estimated)8/4/2021 (Estimated)7/28/2021 (Estimated)8/10/2021 (Estimated)7/29/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Seagen Inc. (NASDAQ:SGEN) EVP Sells $148,540.00 in StockSeagen Inc. (NASDAQ:SGEN) EVP Sells $148,540.00 in Stock
americanbankingnews.com - May 13 at 9:46 PM
Seagen Inc. (NASDAQ:SGEN) Expected to Post Earnings of -$0.60 Per ShareSeagen Inc. (NASDAQ:SGEN) Expected to Post Earnings of -$0.60 Per Share
americanbankingnews.com - May 13 at 1:18 PM
Seagen (NASDAQ:SGEN) Trading Up 5.6%Seagen (NASDAQ:SGEN) Trading Up 5.6%
americanbankingnews.com - May 12 at 2:56 PM
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows - The Motley FoolGot $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows - The Motley Fool
fool.com - May 12 at 10:43 AM
Seagen Inc (SGEN) President and CEO Clay B Siegall Sold $4 million of Shares - Yahoo FinanceSeagen Inc (SGEN) President and CEO Clay B Siegall Sold $4 million of Shares - Yahoo Finance
finance.yahoo.com - May 10 at 3:56 PM
Seagen Inc. (NASDAQ:SGEN) Jumps 2.51%, But Additional Rally May Be ImminentSeagen Inc. (NASDAQ:SGEN) Jumps 2.51%, But Additional Rally May Be Imminent
marketingsentinel.com - May 9 at 1:10 AM
Do Traders Think Seagen Inc (SGEN) Can Turn Around Thursday? - InvestorsObserverDo Traders Think Seagen Inc (SGEN) Can Turn Around Thursday? - InvestorsObserver
investorsobserver.com - May 6 at 5:12 PM
Declining Stock and Solid Fundamentals: Is The Market Wrong About Seagen Inc. (NASDAQ:SGEN)? - NasdaqDeclining Stock and Solid Fundamentals: Is The Market Wrong About Seagen Inc. (NASDAQ:SGEN)? - Nasdaq
nasdaq.com - May 6 at 5:12 PM
Moser Wealth Advisors, LLC Buy - GuruFocus.comMoser Wealth Advisors, LLC Buy - GuruFocus.com
gurufocus.com - May 5 at 11:44 PM
Cullen Buys Berkshire Hathaway - GuruFocus.comCullen Buys Berkshire Hathaway - GuruFocus.com
gurufocus.com - May 5 at 1:43 PM
IFM Investors Pty Ltd Buys Int - GuruFocus.comIFM Investors Pty Ltd Buys Int - GuruFocus.com
gurufocus.com - May 5 at 8:30 AM
Seagen (NASDAQ:SGEN) Hits New 52-Week Low at $133.20Seagen (NASDAQ:SGEN) Hits New 52-Week Low at $133.20
americanbankingnews.com - May 4 at 9:02 PM
Treasurer of the State of Nort - GuruFocus.comTreasurer of the State of Nort - GuruFocus.com
gurufocus.com - May 3 at 11:55 PM
Analysts Have Conflicting Sentiments on These Healthcare Companies: Thermo Fisher (TMO), Vertex Pharmaceuticals (VRTX) and Seagen (SGEN) - Smarter AnalystAnalysts Have Conflicting Sentiments on These Healthcare Companies: Thermo Fisher (TMO), Vertex Pharmaceuticals (VRTX) and Seagen (SGEN) - Smarter Analyst
smarteranalyst.com - May 3 at 8:24 AM
Seagen Inc. (SGEN) CEO Clay Siegall on Q1 2021 Results - Earnings Call Transcript - Seeking AlphaSeagen Inc. (SGEN) CEO Clay Siegall on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 1 at 9:50 AM
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y - Yahoo FinanceSeagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y - Yahoo Finance
finance.yahoo.com - May 1 at 9:50 AM
Seagen (NASDAQ:SGEN) Receives New Coverage from Analysts at Needham & Company LLCSeagen (NASDAQ:SGEN) Receives New Coverage from Analysts at Needham & Company LLC
americanbankingnews.com - April 30 at 3:27 PM
Seagen (NASDAQ:SGEN) Price Target Cut to $160.00 by Analysts at Piper SandlerSeagen (NASDAQ:SGEN) Price Target Cut to $160.00 by Analysts at Piper Sandler
americanbankingnews.com - April 30 at 2:34 PM
Seagen (NASDAQ:SGEN) Shares Up 4.2%Seagen (NASDAQ:SGEN) Shares Up 4.2%
americanbankingnews.com - April 30 at 1:04 PM
Seagen Inc (SGEN) Stock Declines -1.62% This Week; Should You Buy? - InvestorsObserverSeagen Inc (SGEN) Stock Declines -1.62% This Week; Should You Buy? - InvestorsObserver
investorsobserver.com - April 30 at 12:38 PM
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y - NasdaqSeagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y - Nasdaq
nasdaq.com - April 30 at 12:38 PM
Seagen (NASDAQ:SGEN) Now Covered by Needham & Company LLCSeagen (NASDAQ:SGEN) Now Covered by Needham & Company LLC
marketbeat.com - April 30 at 12:15 PM
Seagen Inc. 2021 Q1 - Results - Earnings Call PresentationSeagen Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - April 30 at 11:29 AM
HC Wainwright Stick to Their Buy Rating for Seagen By Investing.com - Investing.comHC Wainwright Stick to Their Buy Rating for Seagen By Investing.com - Investing.com
investing.com - April 30 at 7:38 AM
Seattle Genetics (SGEN) Q1 2021 Earnings Call TranscriptSeattle Genetics (SGEN) Q1 2021 Earnings Call Transcript
fool.com - April 30 at 3:22 AM
Analysts Have Conflicting Sentiments on These Healthcare Companies: Seagen (SGEN) and Agios Pharma (AGIO) - Smarter AnalystAnalysts Have Conflicting Sentiments on These Healthcare Companies: Seagen (SGEN) and Agios Pharma (AGIO) - Smarter Analyst
smarteranalyst.com - April 30 at 2:10 AM
DateCompanyBrokerageAction
5/7/2021Gilead SciencesJefferies Financial GroupReiterated Rating
5/6/2021Gilead SciencesSVB LeerinkBoost Price Target
5/3/2021Gilead SciencesMorgan StanleyBoost Price Target
4/30/2021Gilead SciencesNeedham & Company LLCReiterated Rating
4/1/2021Gilead SciencesSanford C. BernsteinUpgrade
3/30/2021Gilead SciencesRedburn PartnersUpgrade
2/5/2021Gilead SciencesCredit Suisse GroupBoost Price Target
1/4/2021Gilead SciencesGuggenheimUpgrade
12/22/2020Gilead SciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
12/22/2020Gilead SciencesSmith Barney CitigroupLower Price Target
12/18/2020Gilead SciencesTruist FinancialLower Price Target
12/17/2020Gilead SciencesOppenheimerLower Price Target
12/16/2020Gilead SciencesBMO Capital MarketsLower Price Target
12/16/2020Gilead SciencesRobert W. BairdBoost Price Target
12/15/2020Gilead SciencesPiper SandlerLower Price Target
12/8/2020Gilead SciencesJPMorgan Chase & Co.Reiterated Rating
5/13/2021ModernaThe Goldman Sachs GroupBoost Price Target
5/13/2021ModernaChardan CapitalBoost Price Target
5/7/2021ModernaBarclaysBoost Price Target
3/4/2021ModernaBrookline Capital ManagementBoost Price Target
2/26/2021ModernaBank of AmericaReiterated Rating
4/23/2021BiogenHC WainwrightReiterated Rating
4/19/2021BiogenWedbushBoost Price Target
2/17/2021BiogenCantor FitzgeraldLower Price Target
2/5/2021BiogenDZ BankDowngrade
1/29/2021BiogenStifel NicolausUpgrade
12/1/2020BiogenWilliam BlairReiterated Rating
12/1/2020BiogenRoyal Bank of CanadaBoost Price Target
11/9/2020BiogenMizuhoLower Price Target
11/9/2020BiogenCowenDowngrade
5/12/2021BioNTechCanaccord GenuityBoost Price Target
5/11/2021BioNTechBryan, Garnier & CoDowngrade
4/6/2021BioNTechBerenberg BankSet Price Target
10/29/2020BioNTechCommerzbankInitiated Coverage
10/13/2020SeagenJMP SecuritiesBoost Price Target
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.